-

Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences.

  • Jefferies Global Healthcare Conference in London, UK on Tuesday, November 17; fireside chat at 3:00 pm Greenwich Mean Time
  • 9th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 1; fireside chat at 7:30 am Eastern Time

The fireside chats will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the fireside chats will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.

We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.

Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.

Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

Contacts

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Twist Bioscience Corporation

NASDAQ:TWST

Release Versions

Contacts

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Social Media Profiles
More News From Twist Bioscience Corporation

Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2026 ended September 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2026 earnings report and the investor presenta...

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value healthcare company, today announced that a total of 17,681 restricted stock units (“RSUs”) will be granted to 19 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist’s Amended and...

Notice of Proposed Derivative Settlement: Twist Bioscience Corporation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST): UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE IN RE TWIST BIOSCIENCE CORPORATION DERIVATIVE LITIGATION Lead Case No. 1:23-cv-01048-MN SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF TWIST BIOSCIENCE CORPORATION (“TWIST” OR THE “COMPANY”) COMMON STOCK AS OF OCTOBER 15, 2026 (THE “RECORD DATE”). IF YOU WERE A RECORD OR BENEFICIAL OWNER O...
Back to Newsroom